Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07074977 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
A Phase 2 study of Chronic Pruritus of Unknown Origin, sponsored by Galderma R&D.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 18
- Study locations
NCT07074977: Recruiting Phase 2 study of Chronic Pruritus of Unknown Origin, sponsored by Galderma R&D.
NCT07074977 is a Phase 2 study of Chronic Pruritus of Unknown Origin that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07074977, a Phase 2 study of Chronic Pruritus of Unknown Origin, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 18
- Study locations
Study Summary
The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
Primary Outcome
Point Estimate of Population Total Clearance (Cl/F) of nemolizumab will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG nemolizumab
Study Locations (18)
California
- Galderma Investigational Site (site# 8130) - Los Angeles
- Galderma Investigational Site (#9975) - Sacramento
- Galderma Investigational Site (site# 8021) - San Diego
- Galderma Investigational Site (site# 7075) - San Francisco
Florida
- Galderma Investigational Site (#8295) - Miami
- Galderma Investigational Site (site# 7054) - Tampa
Alabama
- Galderma Investigational Site (site# 8893) - Birmingham
Indiana
- Galderma Investigational Site (site# 8142) - Indianapolis
Michigan
- Galderma Investigational Site (site# 8743) - Ann Arbor
Missouri
- Galderma Investigational Site (site# 8521) - Saint Joseph
Nevada
- Galderma Investigational Site (site# 8108) - Las Vegas
New York
- Galderma Investigational Site (site# 7110) - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07074977 shows while recruiting
NCT07074977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Chronic Pruritus of Unknown Origin appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07074977 lists 18 locations in 14 states (California, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT07074977 about?
NCT07074977 is a clinical study titled "Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)". The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
What is the current status of trial NCT07074977?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-10-20. Estimated completion is 2027-01.
What conditions does trial NCT07074977 study?
This clinical trial studies the following conditions: Chronic Pruritus of Unknown Origin.
What interventions are being tested in trial NCT07074977?
The interventions under investigation include: Placebo (DRUG), nemolizumab (DRUG).
Who is sponsoring clinical trial NCT07074977?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07074977 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07074977's enrollment target sits among peer trials
50 1195th of 2000 higher than 741 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI